173 related articles for article (PubMed ID: 17326939)
21. A descriptive study of Guillain-Barré syndrome in high and low Campylobacter jejuni incidence regions of Michigan: 1992-1999.
Church Potter R; Kaneene JB
Neuroepidemiology; 2003; 22(4):245-8. PubMed ID: 12792145
[TBL] [Abstract][Full Text] [Related]
22. Guillain-Barré syndrome associated with the D222E variant of the 2009 pandemic influenza A (H1N1) virus: case report and review of the literature.
Cortese A; Baldanti F; Tavazzi E; Carnevale L; Minoli L; Lozza A; Marchioni E
J Neurol Sci; 2012 Jan; 312(1-2):173-6. PubMed ID: 22000408
[TBL] [Abstract][Full Text] [Related]
23. Clinical and electrophysiological features of the 2007 Guillain-Barré syndrome epidemic in northeast China.
Ye Y; Zhu D; Wang K; Wu J; Feng J; Ma D; Xing Y; Jiang X
Muscle Nerve; 2010 Sep; 42(3):311-4. PubMed ID: 20589890
[TBL] [Abstract][Full Text] [Related]
24. Association of Campylobacter jejuni infection with childhood Guillain-Barré syndrome: a case-control study.
Kalra V; Chaudhry R; Dua T; Dhawan B; Sahu JK; Mridula B
J Child Neurol; 2009 Jun; 24(6):664-8. PubMed ID: 19491112
[TBL] [Abstract][Full Text] [Related]
25. Guillain-Barré syndrome associated with acute hepatitis E infection.
Tse AC; Cheung RT; Ho SL; Chan KH
J Clin Neurosci; 2012 Apr; 19(4):607-8. PubMed ID: 22285113
[TBL] [Abstract][Full Text] [Related]
26. Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study.
Sinha S; Prasad KN; Jain D; Pandey CM; Jha S; Pradhan S
Clin Microbiol Infect; 2007 Mar; 13(3):334-7. PubMed ID: 17391394
[TBL] [Abstract][Full Text] [Related]
27. Guillain-Barré syndrome after influenza vaccination in the United States, a report from the CDC/FDA vaccine adverse event reporting system (1990-2009).
Souayah N; Yacoub HA; Khan HM; Farhad K; Mehyar LS; Maybodi L; Menkes DL; Qureshi AI
J Clin Neuromuscul Dis; 2012 Dec; 14(2):66-71. PubMed ID: 23172385
[TBL] [Abstract][Full Text] [Related]
28. Systematic review of factors associated with the development of Guillain-Barré syndrome 2007-2017: what has changed?
Wachira VK; Peixoto HM; de Oliveira MRF
Trop Med Int Health; 2019 Feb; 24(2):132-142. PubMed ID: 30444562
[TBL] [Abstract][Full Text] [Related]
29. Guillain-Barré syndrome post renal transplant: A systematic review.
Ostman C; Chacko B
Transpl Infect Dis; 2019 Feb; 21(1):e13021. PubMed ID: 30403433
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre syndrome after Campylobacter jejuni enteritis.
Koga M; Gilbert M; Takahashi M; Li J; Koike S; Hirata K; Yuki N
J Infect Dis; 2006 Feb; 193(4):547-55. PubMed ID: 16425134
[TBL] [Abstract][Full Text] [Related]
31. Association study between an outbreak of Guillain-Barre syndrome in Jilin, China, and preceding Campylobacter jejuni infection.
Zhang M; Li Q; He L; Meng F; Gu Y; Zheng M; Gong Y; Wang P; Ruan F; Zhou L; Wu J; Chen L; Fitzgerald C; Zhang J
Foodborne Pathog Dis; 2010 Aug; 7(8):913-9. PubMed ID: 20455754
[TBL] [Abstract][Full Text] [Related]
32. Guillain-Barre syndrome and Campylobacter infection.
Prasad KN; Pradhan S; Nag VL
Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):527-30. PubMed ID: 11944711
[TBL] [Abstract][Full Text] [Related]
33. Hospital admissions for Guillain-Barré syndrome in the United States, 1993-2004.
Frenzen PD
Neuroepidemiology; 2007; 29(1-2):83-8. PubMed ID: 17925599
[TBL] [Abstract][Full Text] [Related]
34. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database.
Tam CC; O'Brien SJ; Petersen I; Islam A; Hayward A; Rodrigues LC
PLoS One; 2007 Apr; 2(4):e344. PubMed ID: 17406668
[TBL] [Abstract][Full Text] [Related]
35. [Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome].
Orlikowski D; Quijano-Roy S; Sivadon-Tardy V; Raphael JC; Gaillard JL
Arch Pediatr; 2006 Dec; 13(12):1561-5. PubMed ID: 17030119
[TBL] [Abstract][Full Text] [Related]
36. Declining Guillain-Barré syndrome after campylobacteriosis control, New Zealand, 1988-2010.
Baker MG; Kvalsvig A; Zhang J; Lake R; Sears A; Wilson N
Emerg Infect Dis; 2012 Feb; 18(2):226-33. PubMed ID: 22304786
[TBL] [Abstract][Full Text] [Related]
37. Acute small fiber neuropathy following Mycoplasma infection: a rare variant of Guillain-Barré syndrome.
Makonahalli R; Seneviratne J; Seneviratne U
J Clin Neuromuscul Dis; 2014 Jun; 15(4):147-51. PubMed ID: 24872212
[TBL] [Abstract][Full Text] [Related]
38. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
Souayah N; Nasar A; Suri MF; Qureshi AI
J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
[TBL] [Abstract][Full Text] [Related]
39. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies.
Kimoto K; Koga M; Odaka M; Hirata K; Takahashi M; Li J; Gilbert M; Yuki N
Neurology; 2006 Nov; 67(10):1837-43. PubMed ID: 17130419
[TBL] [Abstract][Full Text] [Related]
40. Recurrent Guillain-Barre syndrome following vaccination.
Baxter R; Lewis N; Bakshi N; Vellozzi C; Klein NP;
Clin Infect Dis; 2012 Mar; 54(6):800-4. PubMed ID: 22267712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
